Related Experiment Videos
Canavan disease: a white matter disorder.
Shalini Kumar1, Natalia S Mattan, Jean de Vellis
1Department of Neurobiology, Mental Retardation Research Center, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, California 90095-7332, USA.
Summary
Canavan disease (CD) involves myelin loss due to ASPA gene mutations, impacting oligodendrocyte function. Gene therapy attempts have shown limited success, highlighting the need for further research into CNS targets for effective treatment.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Leukodystrophies are white matter diseases characterized by myelin defects, stemming from genetic mutations affecting oligodendrocytes or secondary to neuronal/astroglial dysfunction.
- Canavan disease (CD) is a leukodystrophy caused by mutations in the aspartoacylase (ASPA) gene, primarily affecting oligodendrocytes in the central nervous system (CNS).
- CD shares pathophysiological similarities with other myelin-related genetic disorders and animal models, indicating pleiotropic effects of single gene mutations on myelin gene expression.
Purpose of the Study:
- To describe the pathophysiological parameters of Canavan disease (CD).
- To review the challenges and outcomes of adeno-associated virus vector (AAV)-ASPA gene therapy for CD.
- To identify critical developmental questions regarding CNS targets for CD onset and progression.
Main Methods:
- Review of existing literature on leukodystrophies, Canavan disease, and gene therapy approaches.
- Analysis of pathophysiological mechanisms in CD, comparing it to other myelin disorders.
- Evaluation of outcomes from AAV-ASPA gene therapy trials in animal models and initial human attempts.
Main Results:
- ASPA gene mutations in CD lead to oligodendrocyte dysfunction and white matter abnormalities, similar to other myelin-related disorders.
- Early gene therapy attempts using AAV-ASPA in animal models showed reduced N-acetyl L-aspartate and altered motor functions, but failed to resolve white matter sponginess.
- Despite improved viral vectors and early developmental gene delivery, significant therapeutic success for CD remains elusive.
Conclusions:
- Canavan disease presents complex pathophysiological challenges that current gene therapy strategies have not fully overcome.
- Further research is essential to identify specific CNS regions and cell lineages as targets for effective CD treatment.
- Addressing pivotal developmental questions is crucial for advancing gene therapy success in leukodystrophies like Canavan disease.